Lennox Acquires Focus Scientific Solutions

Spectrum Science Acquires Return on Focus

September 30, 2025

Marketing & Advertising

Spectrum Science has acquired Return on Focus, a strategic marketing consultancy that provides evidence-based brand positioning and strategic services to pharmaceutical and biotech companies. The acquisition strengthens Spectrum’s strategic and commercial capabilities—bringing Return on Focus’ data-driven positioning expertise into Spectrum’s integrated healthcare marketing platform; Dan Reinhardt and Abby Manning will continue to lead the ROF team.

Continuity Biosciences Acquires Focal Medical

June 4, 2025

Biotechnology

Continuity Biosciences, LLC has acquired Focal Medical, Inc., a North Carolina–based biopharmaceutical company developing iontophoresis-based, site-specific chemotherapy delivery for pancreatic cancer. The acquisition transfers Focal Medical's patent estate, device platform, equipment, licensing agreements and key personnel to Continuity as it expands its drug‑delivery and device-enabled therapeutics capabilities and advances the lead program toward clinical trials.

Eurofins Scientific Acquires Infinity Laboratories

September 16, 2024

Healthcare Services

Eurofins Scientific has completed the acquisition of Infinity Laboratories, a U.S.-based contract testing group that operates eight laboratories and employs approximately 100 staff. The deal expands Eurofins' microbiology and package testing footprint across the United States, enhancing its BioPharma and Medical Device testing capabilities and geographic coverage.

Bausch + Lomb Acquires AcuFocus, Inc.

January 17, 2023

Medical Devices

Bausch + Lomb Corporation has acquired AcuFocus, Inc. through an affiliate via a merger with AcuFocus’s parent company. The acquisition adds AcuFocus’s IC‑8 Apthera small‑aperture extended‑depth‑of‑focus intraocular lens to Bausch + Lomb’s surgical portfolio to expand capabilities in premium cataract IOL offerings.

Full-Life Technologies Acquires Focus‑X Therapeutics

November 28, 2022

Biotechnology

Full‑Life Technologies, a global radiotherapeutics company, agreed to acquire New Jersey‑based Focus‑X Therapeutics to expand its peptide‑focused radiopharmaceutical pipeline. Focus‑X shareholders are eligible for an upfront payment plus up to $245 million in development, regulatory and sales milestones and royalties; the deal was expected to close in Q1 2023.

Carlyle Acquires Majority Stake in Sciens Building Solutions

November 9, 2021

Industrial Services

Funds managed by global investment firm Carlyle acquired a majority stake in Sciens Building Solutions from Huron Capital, with Sciens' senior management and Huron retaining minority equity and a board seat. The investment will support Sciens' growth strategy — accelerating organic investment and M&A to expand its fire and life safety platform across commercial, institutional and government end markets. Terms were not disclosed.